Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21737968 | 0.88 | GRIN2B (0.48) | GRIN2BDRD2DRD4DRD3KMT2A | |
| SCHEMBL16497761 | 0.83 | CACNA1B (0.51) | GRIN2BDRD2DRD4DRD3KMT2A | |
| SCHEMBL2421730 | 0.83 | CACNA1B (0.51) | GRIN2BDRD2DRD4DRD3KMT2A | |
| SCHEMBL2420238 | 0.83 | CACNA1B (0.51) | GRIN2BDRD2DRD4DRD3KMT2A | |
| SCHEMBL2082398 | 0.82 | KMT2A (0.57) | GRIN2BDRD2KMT2AL3MBTL1 | |
| SCHEMBL18423386 | 0.81 | ROCK2 (0.49) | DRD2DRD4DRD3KMT2ASIGMAR1 | |
| SCHEMBL16032775 | 0.81 | POLB (0.47) | GRIN2BDRD2DRD4DRD3KMT2A | |
| SCHEMBL16032773 | 0.81 | POLB (0.47) | GRIN2BDRD2DRD4DRD3KMT2A | |
| SCHEMBL18423389 | 0.81 | ROCK2 (0.49) | DRD2DRD4DRD3KMT2ASIGMAR1 | |
| SCHEMBL16032771 | 0.81 | POLB (0.47) | GRIN2BDRD2DRD4DRD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902779-A1 | PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE | F. Hoffmann-La Roche AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020136188-A1 | PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-02 | — | — | WO | disclosed |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-7652021-B2 | (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| EP-1664031-B1 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | SANOFI-AVENTIS (FR) | 2006-12-07 | — | — | US | disclosed |
| EP-1664031-A2 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021536-A2 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | SANOFI-AVENTIS (FR) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | DPP4, DPP7, DPP9 | GRIN2B 1852/4885DRD2 2579/4885DRD4 884/4885 |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | DPP4, DPP7, DPP9 | GRIN2B 1852/4885DRD2 2579/4885DRD4 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.